BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 29654229)

  • 1. Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling.
    Oldrini B; Curiel-García Á; Marques C; Matia V; Uluçkan Ö; Graña-Castro O; Torres-Ruiz R; Rodriguez-Perales S; Huse JT; Squatrito M
    Nat Commun; 2018 Apr; 9(1):1466. PubMed ID: 29654229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target.
    Cook PJ; Thomas R; Kannan R; de Leon ES; Drilon A; Rosenblum MK; Scaltriti M; Benezra R; Ventura A
    Nat Commun; 2017 Jul; 8():15987. PubMed ID: 28695888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pipeline for rapidly generating genetically engineered mouse models of pancreatic cancer using in vivo CRISPR-Cas9-mediated somatic recombination.
    Ideno N; Yamaguchi H; Okumura T; Huang J; Brun MJ; Ho ML; Suh J; Gupta S; Maitra A; Ghosh B
    Lab Invest; 2019 Jul; 99(8):1233-1244. PubMed ID: 30728464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.
    Johansen AK; Molenaar B; Versteeg D; Leitoguinho AR; Demkes C; Spanjaard B; de Ruiter H; Akbari Moqadam F; Kooijman L; Zentilin L; Giacca M; van Rooij E
    Circ Res; 2017 Oct; 121(10):1168-1181. PubMed ID: 28851809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Versatile and precise gene-targeting strategies for functional studies in mammalian cell lines.
    Wassef M; Luscan A; Battistella A; Le Corre S; Li H; Wallace MR; Vidaud M; Margueron R
    Methods; 2017 May; 121-122():45-54. PubMed ID: 28499832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P53 ICE CRIM mouse: a tool to generate mutant allelic series in somatic cells and germ lines for cancer studies.
    Fan HH; Yu IS; Lin YH; Wang SY; Liaw YH; Chen PL; Yang TL; Lin SW; Chen YT
    FASEB J; 2019 Apr; 33(4):5571-5584. PubMed ID: 30640520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
    Vermersch E; Jouve C; Hulot JS
    Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision genome editing in the CRISPR era.
    Salsman J; Dellaire G
    Biochem Cell Biol; 2017 Apr; 95(2):187-201. PubMed ID: 28177771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome editing using CRISPR/Cas9-based knock-in approaches in zebrafish.
    Albadri S; Del Bene F; Revenu C
    Methods; 2017 May; 121-122():77-85. PubMed ID: 28300641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exome sequencing in the knockin mice generated using the CRISPR/Cas system.
    Nakajima K; Kazuno AA; Kelsoe J; Nakanishi M; Takumi T; Kato T
    Sci Rep; 2016 Oct; 6():34703. PubMed ID: 27698470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9 editing of the genome for cancer modeling.
    Guernet A; Grumolato L
    Methods; 2017 May; 121-122():130-137. PubMed ID: 28288827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly Efficient Mouse Genome Editing by CRISPR Ribonucleoprotein Electroporation of Zygotes.
    Chen S; Lee B; Lee AY; Modzelewski AJ; He L
    J Biol Chem; 2016 Jul; 291(28):14457-67. PubMed ID: 27151215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of unwanted CRISPR-Cas9 editing by co-administration of catalytically inactivating truncated guide RNAs.
    Rose JC; Popp NA; Richardson CD; Stephany JJ; Mathieu J; Wei CT; Corn JE; Maly DJ; Fowler DM
    Nat Commun; 2020 Jun; 11(1):2697. PubMed ID: 32483117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysing the outcome of CRISPR-aided genome editing in embryos: Screening, genotyping and quality control.
    Mianné J; Codner GF; Caulder A; Fell R; Hutchison M; King R; Stewart ME; Wells S; Teboul L
    Methods; 2017 May; 121-122():68-76. PubMed ID: 28363792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field.
    He ZY; Men K; Qin Z; Yang Y; Xu T; Wei YQ
    Sci China Life Sci; 2017 May; 60(5):458-467. PubMed ID: 28527117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome Editing Reveals Glioblastoma Addiction to MicroRNA-10b.
    El Fatimy R; Subramanian S; Uhlmann EJ; Krichevsky AM
    Mol Ther; 2017 Feb; 25(2):368-378. PubMed ID: 28153089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of genome editing through CRISPR-Cas9 engineering.
    Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF
    Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome editing via delivery of Cas9 ribonucleoprotein.
    DeWitt MA; Corn JE; Carroll D
    Methods; 2017 May; 121-122():9-15. PubMed ID: 28410976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome Editing with AAV-BR1-CRISPR in Postnatal Mouse Brain Endothelial Cells.
    Song X; Cui Y; Wang Y; Zhang Y; He Q; Yu Z; Xu C; Ning H; Han Y; Cai Y; Cheng X; Wang J; Teng Y; Yang X; Wang J
    Int J Biol Sci; 2022; 18(2):652-660. PubMed ID: 35002515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision genome editing using CRISPR-Cas9 and linear repair templates in C. elegans.
    Paix A; Folkmann A; Seydoux G
    Methods; 2017 May; 121-122():86-93. PubMed ID: 28392263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.